Press "Enter" to skip to content

Intra-Cellular Therapies Files US Application For Expanded Use Of Lumateperone In Bipolar Settings

  • Intra-Cellular Therapies Inc (NASDAQ: ITCIsubmits CAPLYTA (lumateperone) supplemental marketing application to the FDA to treat depressive episodes associated with bipolar I or II disorder in adults.
  • The application seeks approval for two indications of CAPLYTA; as monotherapy and as adjunctive therapy with lithium or valproate.
  • The Company anticipates an FDA target action date for the application in the second half of 2021.
  • CAPLYTA is indicated for the treatment of schizophrenia in adults.
  • Price Action: ITCI decreased 1.70% at $38.84 in market trading hours on the last check Monday.

This post was originally published on this site

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *